Inactive Instrument

KARA THER

Equities

KRTX

US48576A1007

Karuna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 22, 2024 at 06:40 am EST

Karuna Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 433.68 million compared to USD 276.34 million a year ago. Basic loss per share from continuing operations was USD 11.73 compared to USD 8.74 a year ago.

Latest news about KARA THER

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from S&P Biotechnology Select Industry Index	Mar. 18	CI
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from S&P TMI Index	Mar. 18	CI
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from S&P Global BMI Index	Mar. 18	CI
Bristol-Myers Squibb Completes Karuna Therapeutics Acquisition	Mar. 18	MT
PureTech Health: Bristol Myers Squibb Wraps Up $14 Billion Acquisition of Karuna	Mar. 18	MT
Karuna Therapeutics, Inc. and Miramar Merger Sub Inc. Announce Management Changes	Mar. 18	CI
Bristol Myers: completes acquisition of Karuna Therapeutics	Mar. 18	CF
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index	Mar. 17	CI
Bristol-Myers Squibb Company completed the acquisition of Karuna Therapeutics, Inc. from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. and others.	Mar. 17	CI
Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Biotechnology Index	Mar. 14	CI
Karuna Therapeutics Q4 Loss Widens	Feb. 22	MT
Karuna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Karuna Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Bristol Myers Squibb Reportedly Eyeing $13 Billion from Bond Sale Launched Wednesday	Feb. 14	MT
Bristol-Myers Squibb's New Product Performance Mixed as Headwinds Persist, Morgan Stanley Says	Feb. 05	MT
Bristol Myers posts better-than-expected 4th-quarter results	Feb. 02	RE
North American Morning Briefing : Cautious Start -2-	Jan. 29	DJ
Mizuho Downgrades Karuna Therapeutics to Neutral From Buy, Raises Price Target to $330 From $245	Jan. 26	MT
Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development	Jan. 16	CI
Karuna Therapeutics Insider Sold Shares Worth $4,752,150, According to a Recent SEC Filing	Jan. 09	MT
Bristol-Myers Squibb Plans 16 New Products by 2030, CEO says	Jan. 08	MT
Bristol Myers expects to launch 16 new products through 2030 - CEO	Jan. 08	RE
Deutsche Bank Downgrades Karuna Therapeutics to Hold From Buy, Adjusts Price Target to $330 From $227	Jan. 02	MT
UBS Raises Price Target on Karuna Therapeutics to $330 From $197, Keeps Neutral Rating	Jan. 02	MT
North American Morning Briefing : Stock Futures Gain as 2023 Draws to a Close	Dec. 29	DJ

Chart KARA THER

Duration

Period

More charts

Company Profile

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline is primarily built on the therapeutic potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS), and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. The Company is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease (AD). The Company is also engaged in developing its investigational TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and plan to provide details regarding the expected development of KAR-2618.

Sector

More about the company